Diabetic kidney disease (DKD), a major cause of end-stage renal disease, affects 30–40 % of individuals with diabetes, a condition projected to impact 783 million people by 2025. This study investigated the effects of curcumin supplementation on renal function and glucose metabolism in alloxan-induced diabetic male Wistar rats. Forty-five rats (150–200 g) were divided into five groups (n = 9): Group A (Control), Group B (Alloxan only), Group C (Alloxan + Metformin), Group D (Alloxan + Curcumin), and Group E (Curcumin only). Diabetes was induced by alloxan (150 mg/kg, intraperitoneally), and blood glucose levels were monitored after 72 h. Groups C, D, and E received metformin (100 mg/kg) or curcumin (100 mg/kg) daily for 4 weeks. Posttreatment, fasting blood samples were collected to assess blood glucose, insulin, and renal function markers, including serum urea, creatinine, and electrolytes (Na+, K+, Clˉ, and HCO3ˉ). Additionally, glucose metabolic enzymes—hexokinase, fructokinase, and pyruvate kinase—were analysed in liver and muscle tissues. The results revealed that alloxan-induced diabetes significantly elevated the serum urea, creatinine, and electrolytes. Curcumin treatment significantly reduced these markers and corrected electrolyte imbalances. It also increased glucose metabolic enzyme activities, increased GLUT4 protein expression in muscle tissues, and reduced insulin resistance, as indicated by the HOMA-IR scores. These findings suggest that curcumin supplementation improves glucose metabolism, reduces inflammation, and preserves renal function, making it a potential therapeutic approach for diabetic nephropathy and an adjuvant for diabetes treatment.
扫码关注我们
求助内容:
应助结果提醒方式:
